All Posts
  • Interviews
1 min read

Graphite Bio co-founder debuts Treg cell therapy startup with $75M, aims to ‘trick’ immune system into resetting

On this page

Share

Tr1x launched from stealth Wednesday with $75 million to tackle graft-versus-host disease in addition to inflammatory and autoimmune conditions.

Related Articles

Explore posts connected to this topic

View Resources

CIRM approves more than $60 million to support clinical and preclinical development awards

South San Francisco, CA, June 25, 2026 – The California Institute for Regenerative Medicine (CIRM) governing board today approved funding...

  • Press Releases

Tr1X to Present New Clinical and Preclinical Data on Engineered Tr1 Treg Cell Therapies at ASGCT 2026

SAN DIEGO–(BUSINESS WIRE)–Tr1X, Inc., a clinical-stage autoimmune and inflammatory disease

  • Press Releases

Bag of Tr1Xs: Off-the-Shelf Type 1 Treg Shows Phase I Promise for GvHD

In a clinical first, Tr1X Bio showed immune reconstitution and

  • Interviews

South San Francisco, CA, June 25, 2026 – The California

  • Press Releases

SAN DIEGO–(BUSINESS WIRE)–Tr1X, Inc., a clinical-stage autoimmune and inflammatory disease

  • Press Releases

In a clinical first, Tr1X Bio showed immune reconstitution and

  • Interviews